Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Dürr

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Methods in Enzymology|June 24, 2006
Structure-function analysis of SWI2/SNF2 enzymesHarald Dürr, Karl-Peter Hopfner
Biochemistry|February 23, 2005
Chromophore exchange in the LOV2 domain of the plant photoreceptor phototropin1 from oatHarald Dürr, Michael Salomon, Wolfhart Rüdiger
Nucleic Acids Research|February 13, 2008
Conformational changes of a Swi2/Snf2 ATPase during its mechano-chemical cycleRobert Lewis, Harald Dürr, Karl-Peter Hopfner, et al.
Nucleic Acids Research|August 29, 2006
Snf2 family ATPases and DExx box helicases: differences and unifying concepts from high-resolution crystal structuresHarald Dürr, Andrew Flaus, Tom Owen-Hughes, et al.
Cell|May 11, 2005
X-ray structures of the Sulfolobus solfataricus SWI2/SNF2 ATPase core and its complex with DNAHarald Dürr, Christian Körner, Marisa Müller, et al.
Journal for Immunotherapy of Cancer|March 16, 2022
The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activationEva Sum, Moritz Rapp, Harald Dürr, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2011
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodiesWolfgang Schaefer, Jörg T Regula, Monika Bähner, et al.
The Biochemical Journal|December 3, 2011
Allosteric antibody inhibition of human hepsin proteaseTobias Koschubs, Stefan Dengl, Harald Dürr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor ImmunityEva Sum, Moritz Rapp, Philipp Fröbel, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Methods in Enzymology|June 24, 2006
Structure-function analysis of SWI2/SNF2 enzymesHarald Dürr, Karl-Peter Hopfner
Biochemistry|February 23, 2005
Chromophore exchange in the LOV2 domain of the plant photoreceptor phototropin1 from oatHarald Dürr, Michael Salomon, Wolfhart Rüdiger
Nucleic Acids Research|February 13, 2008
Conformational changes of a Swi2/Snf2 ATPase during its mechano-chemical cycleRobert Lewis, Harald Dürr, Karl-Peter Hopfner, et al.
Nucleic Acids Research|August 29, 2006
Snf2 family ATPases and DExx box helicases: differences and unifying concepts from high-resolution crystal structuresHarald Dürr, Andrew Flaus, Tom Owen-Hughes, et al.
Cell|May 11, 2005
X-ray structures of the Sulfolobus solfataricus SWI2/SNF2 ATPase core and its complex with DNAHarald Dürr, Christian Körner, Marisa Müller, et al.
Journal for Immunotherapy of Cancer|March 16, 2022
The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activationEva Sum, Moritz Rapp, Harald Dürr, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2011
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodiesWolfgang Schaefer, Jörg T Regula, Monika Bähner, et al.
The Biochemical Journal|December 3, 2011
Allosteric antibody inhibition of human hepsin proteaseTobias Koschubs, Stefan Dengl, Harald Dürr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor ImmunityEva Sum, Moritz Rapp, Philipp Fröbel, et al.
Pageof 1